MedTrace Logo

Real World Evidence of Long-term Safety and Efficacy in Patients Treated With Durvalumab After Concurrent Chemoradiation for Unresectable Stage III NSCLC

NCT03995875 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 529

Last updated 2024-12-05

No results posted yet for this study

Summary

This observational study is designed to assess the long term safety of the durvalumab treatment period including subsequent treatment period and demonstrate the efficacy of patients treated with durvalumab following chemoradiation therapy in the real world.

Conditions

  • Carcinoma, Non-Small-Cell Lung

Sponsors & Collaborators

  • Japan Lung Cancer Society

    collaborator OTHER

  • AstraZeneca

    lead INDUSTRY

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-25
Primary Completion
2024-01-11
Completion
2024-01-11

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03995875 on ClinicalTrials.gov